Search PubMed⌕ Search

Biomedical subjects

R E Falk

Publications and source records attributed to R E Falk.

150 records · Page 9Linked to original sources

Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity.

PURPOSE: Aminoglycoside-induced deafness caused by mutations in the mitochondrial 12S ribosomal RNA gene has been described in a number of Asian patients. The purpose of the current study is to analyze ethnically diverse patients in the United States with hearing loss after aminoglycoside exposure for presence or absence of these mitochondrial DNA mutations, and establish the frequency and clinical presentation associated with them. PATIENTS AND METHODS: Clinical histories, medical records, and blood samples were obtained from 41 unrelated American individuals with hearing loss after aminoglycoside exposure. DNA was extracted from the blood of these individuals, amplified by the polymerase chain reaction, and analyzed for mitochondrial ribosomal RNA gene mutations by allele-specific oligonucleotide hybridization, restriction fragment length polymorphism analysis, and sequencing. RESULTS: The nucleotide 1555 A-->G mutation was identified in 7 of 41 individuals (17%). None of the other known mutations was found. The ethnic origin of the individuals with predisposing mutations included Caucasians, Hispanics, and Asians. Four of the 7 patients with the 1555 A-->G mutation had a family history of aminoglycoside-induced ototoxicity. Particularly unexpected was the late onset of hearing loss in 3 of these patients, years after the aminoglycoside exposure. The 12S ribosomal RNA gene was sequenced in these patients, and a second sequence change that could be responsible for the milder phenotype was detected in 1 of the 3 patients. CONCLUSION: These findings imply that a significant proportion of patients with aminoglycoside-induced ototoxicity harbor mutations in the 12S rRNA gene, which can be detected by DNA screening. Also, the majority of these hearing losses could have been easily prevented by the simple taking of a clinical history. In these individuals, a genetic susceptibility to the ototoxic effects of aminoglycosides can be diagnosed, and deafness can be prevented in maternal relatives by avoidance of these antibiotics.

Adult↗

Randomized trial of chemoimmunotherapy for resectable and non-resectable gastrointestinal cancer.

Two trials were carried out in order to compare, in two similar groups of patients, the efficacity of 5-fluorouracil (5FU) with or without BCG. The first trial comprised 159 patients with different forms of carcinoma. The differences in survival rate between the 77 patients treated with 5FU and the 82 patients who had received 5FU and BCG seem to be in favour of the combined treatment, but are not statistically significant. The second trial (20 cases treated with 5FU and 23 cases treated with 5FU and BCG) concerned patients with Dukes' Stage B and C colorectal cancer; the results of the combined treatment are clearly more favourable.

BCG Vaccine↗

The efficacy of phloridzin and phloretin on tumor cell growth.

This study utilized phloridzin (P1) and its aglucone phloretin (P2), two known inhibitors of glucose transmembrane transport, to inhibit tumor cell growth in vivo. The efficacy of hydrazine sulfate as an anticachexic agent was also evaluated. Utilizing the rat mammary adenocarcinoma and Fischer bladder cell carcinoma cell lines, it has been shown that the i.p. administration of P1 and P2 can produce significant differences in mean tumor diameters as compared to the untreated controls.

Adenocarcinoma↗

Phloridzin and phloretin inhibition of 2-deoxy-D-glucose uptake by tumor cells in vitro and in vivo.

Utilizing the rat mammary adenocarcinoma and Fischer bladder cell carcinoma cell lines, this study demonstrated the ability of two known glucose transport inhibitors, phloridzin (P1) and its aglucone, phloretin (P2), to block glucose transport into whole viable tumor cells in vitro and tumor tissues in vivo. This work represents the first in a series of experiments designed to explore the efficacy of P1 and P2 administration in restraining tumor cell growth via the inhibition of glucose transmembrane transport.

Adenocarcinoma↗